BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10487030)

  • 1. [Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with glycyrrhizin against Mycobacterium avium complex infection in mice].
    Shimizu T; Tomioka H; Sato K; Akaki T; Ogasawara K; Kawahara S
    Kekkaku; 1999 Aug; 74(8):617-21. PubMed ID: 10487030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice].
    Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1998 Aug; 73(8):501-6. PubMed ID: 9780605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
    Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice.
    Shimizu T; Tomioka H; Sato K; Sano C; Akaki T; Dekio S; Yamada Y; Kamei T; Shibata H; Higashi N
    Antimicrob Agents Chemother; 1999 Mar; 43(3):514-9. PubMed ID: 10049260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Profiles of expression of the therapeutic efficacy of KRM-1648 in mice infected with Mycobacterium avium complex at different challenge doses].
    Shimizu T; Ogasawara K; Sato K; Sano C; Tomioka H
    Kekkaku; 2001 May; 76(5):413-8. PubMed ID: 11449696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
    Sato K; Tomioka H
    Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of bacterial regrowth at the sites of infection in Mycobacterium avium complex-infected mice during treatment with chemotherapeutic agents].
    Sato K; Tomioka H; Maw WW; Saito H
    Kekkaku; 1995 Dec; 70(12):673-8. PubMed ID: 8551714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice].
    Tomioka H; Sato K; Saito H; Hidaka T
    Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice].
    Saito H; Tomioka H; Sato K; Hidaka T
    Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Sato K; Ogasawara K; Akaki T; Tomioka H
    Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of the Chinese traditional medicines "mao-bushi-saishin-to" and "yokuinin" on the antimycobacterial activity of murine macrophages against Mycobacterium avium complex infection].
    Shimizu T; Sano C; Akaki T; Ogasawara K; Sato K; Tomioka H
    Kekkaku; 1999 Sep; 74(9):661-6. PubMed ID: 10535279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice.
    Sano C; Shimizu T; Sato K; Kawauchi H; Kawahara S; Tomioka H
    Antimicrob Agents Chemother; 1999 Feb; 43(2):360-4. PubMed ID: 9925533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemoprophylaxis against Mycobacterium avium complex infection induced in mice].
    Saito H; Murakami K; Kobayashi K; Gidoh M; Hidaka T; Kwon HH
    Kekkaku; 1999 Sep; 74(9):677-81. PubMed ID: 10535281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice.
    Tomioka H; Sato K; Shimizu T; Sano C; Akaki T; Saito H; Fujii K; Hidaka T
    Antimicrob Agents Chemother; 1997 Feb; 41(2):357-62. PubMed ID: 9021192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice.
    Tomioka H; Saito H; Sato K; Yamane T; Yamashita K; Hosoe K; Fujii K; Hidaka T
    Antimicrob Agents Chemother; 1992 Feb; 36(2):387-93. PubMed ID: 1605603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
    Doi N
    Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
    Sato K; Akaki T; Tomioka H
    J Antimicrob Chemother; 1998 Jan; 41(1):77-83. PubMed ID: 9511040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered in various frequencies per week in Mycobacterium intracellulare-infected mice].
    Tomioka H; Sato K; Saito H; Dekio S; Hidaka T
    Kekkaku; 1993 Nov; 68(11):683-6. PubMed ID: 8264123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.